secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2024-10-07T23:59:59+00:00
Accession:  0001193125-24-233294
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Bio provides updated clinical milestones: RESET data at ACR 2024, MG data H1 2025
--------------------------------------------------------------------------------

- Additional clinical data from RESET-SLE and RESET-Myositis trials to be presented at ACR Convergence 2024 in November.
- Initial clinical data from the RESET-SSc trial also scheduled for ACR Convergence 2024.
- Initial clinical data from the RESET-MG trial anticipated in the first half of 2025.
- Updated corporate presentation posted on the company website with these milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312524233294/0001193125-24-233294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312524233294/d899909d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-233294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer